(Q37131229)

18 August 2017

1 reference

title

Current status of symptomatic medical therapy in Parkinson's disease (English)

1 reference

18 August 2017

1 reference

1

Stewart A Factor

1 reference

18 August 2017

1 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

5

1 reference

18 August 2017

2

1 reference

18 August 2017

164-180

1 reference

https://scigraph.springernature.com/pub.10.1016/j.nurt.2007.12.001

18 August 2017

0 references

cites work

Long-term follow-up of impulse control disorders in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Tolcapone: an efficacy and safety review (2007)

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Drug Insight: new drugs in development for Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

New pharmacologic horizons in the treatment of Parkinson disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Safinamide: from molecular targets to a new anti-Parkinson drug

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Association of dopamine agonist use with impulse control disorders in Parkinson disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Does levodopa slow or hasten the rate of progression of Parkinson's disease?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Pathological gambling caused by drugs used to treat Parkinson disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Sleep issues in Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Levodopa and the progression of Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Atypical cancer pattern in patients with Parkinson's disease.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Subcutaneously administered apomorphine: pharmacokinetics and metabolism

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Apomorphine in Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

A controlled trial of rotigotine monotherapy in early Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Pramipexole in treatment-resistant depression: a 16-week naturalistic study

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

L-DOPA: From a biologically inactive amino acid to a successful therapeutic agent

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Plasma homocysteine as a risk factor for dementia and Alzheimer's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Parkinson's Disease: Initial Treatment with Levodopa or Dopamine Agonists

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Pramipexole-induced somnolence and episodes of daytime sleep

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Comparison of pramipexole, fluoxetine, and placebo in patients with major depression

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Sleep attacks (sleep episodes) with pergolide

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Waking up to sleep episodes in Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Tolcapone and hepatotoxic effects. Tasmar Advisory Panel

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Levodopa in the treatment of Parkinson's disease: a consensus meeting

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Treatment of Parkinsonism With Levodopa

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Deprenyl as symptomatic therapy in Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

14 September 2017

The serotonin syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (madopar®) in the treatment of Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Management of impulse control disorders in Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Clinical trials with rasagiline: evidence for short-term and long-term effects

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Levodopa: is toxicity a myth?

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Pharmacologic profile of ropinirole: a nonergoline dopamine agonist

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

The role of dopamine agonists in early Parkinson's disease

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Bromocriptine in Parkinsonism.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Modification of Parkinsonism--chronic treatment with L-dopa

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Distinct monoamine oxidase A and B populations in primate brain.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Sleep disorders and sleep effect in Parkinson's disease.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

The history of drugs for the treatment of Parkinson's disease

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Levodopa with benserazide or carbidopa in Parkinson disease

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084161

Dopamine miracle: from brain homogenate to dopamine replacement

27 June 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Treatment with levodopa and risk for malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Homocysteine, MTHFR 677C-->T polymorphism, and risk of ischemic stroke: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Levodopa-induced hyperhomocysteinaemia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Endothelial function markers in parkinsonian patients with hyperhomocysteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

FAST TRACK: daytime sleepiness in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Driving in Parkinson's disease: mobility, accidents, and sudden onset of sleep at the wheel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Sudden uncontrollable somnolence and medication use in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Disabling repetitive behaviors in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Pathological gambling associated with dopamine agonist therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Prevalence of pathological gambling in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Gambling and Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Pathologic gambling in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Entacapone-induced hepatotoxicity and hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Results from a 2-year centralized tolcapone liver enzyme monitoring program

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Duodenal levodopa infusion in Parkinson's disease--long-term experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Prospective prevalence of pathologic gambling and medication association in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Prevalence of repetitive and reward-seeking behaviors in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.12.001

Dopamine agonist therapy for Parkinson disease and pathological gambling

21 January 2018

1 reference

12 December 2020

Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years

1 reference

12 December 2020

A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group

1 reference

12 December 2020

Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial

1 reference

12 December 2020

1 reference

12 December 2020

Drug-delivery products and the Zydis fast-dissolving dosage form

1 reference

12 December 2020

Clinical features associated with impulse control disorders in Parkinson disease

1 reference

12 December 2020

Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease

1 reference

12 December 2020

Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease

1 reference

12 December 2020

Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients

1 reference

12 December 2020

Young onset Parkinson's disease

1 reference

12 December 2020

Impulse control disorders and dopaminergic drugs

1 reference

12 December 2020

Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial

1 reference

12 December 2020

1 reference

12 December 2020

Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal

1 reference

12 December 2020

1 reference

12 December 2020

Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group

1 reference

12 December 2020

Hypersexuality with Antiparkinsonian Therapy

1 reference

12 December 2020

Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study

1 reference

12 December 2020

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I

1 reference

12 December 2020

Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study

1 reference

12 December 2020

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

12 December 2020

Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations

1 reference

12 December 2020

Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline

1 reference

12 December 2020

Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease

1 reference

12 December 2020

Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group

1 reference

12 December 2020

1 reference

12 December 2020

Effect of deprenyl on the progression of disability in early Parkinson's disease

1 reference

12 December 2020

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

1 reference

12 December 2020

10.1016/J.NURT.2007.12.001

Identifiers

DOI

1 reference

PMCID

5084161

Dimensions Publication ID

18 August 2017

0 references

1 reference

18 August 2017

1 reference

PMCID

5084161